Breast cancer is the most common cancer in women worldwide and the second most common cancer overall. Although it can now be treated with drugs, many of these drugs mysteriously stop working after some time, causing a relapse. Now a…
Read More
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials,…
Read More
Liquid Biopsy After Hepatectomy Promising Aid in Metastatic Colorectal Cancer
NEW YORK (Reuters Health) – Liquid biopsy following resection of colorectal liver metastases allows non-invasive molecular profiling which may help spot hard-to-detect remaining disease, according to Houston-based researchers. Dr. Yun Shin Chun told Reuters Health by email that analysis of…
Read More
Delayed Start of HIV Therapy Tied to Small Increase in Risk of AIDS-Related Cancers
NEW YORK (Reuters Health) – Delaying the initiation of antiretroviral therapy (ART) in HIV-positive patients is associated with a small increase in risk for AIDS-related cancer, according to new research that supports long-standing guidance to start ART immediately regardless of…
Read More
Researchers study impact of pandemic cancer screening pause
John Abraham’s colonoscopy was postponed for several months because of the pandemic. When he finally got it, doctors found a growth too big to be removed safely during the scope exam. He had to wait several weeks for surgery, then…
Read More
U.S. FDA Expands Approval of Pfizer’s Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
NEW YORK–(BUSINESS WIRE) March 03, 2021 — The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for Lorbrena® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase…
Read More
Detecting hidden circulating tumor cells in non-small cell lung cancer patients
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected…
Read More
New inhibitor makes drug-resistant tumor cells respond again to chemotherapy
A new substance could improve the treatment of persistent cancers. Researchers at Martin Luther University Halle-Wittenberg (MLU) and the University of Greifswald have developed a new inhibitor that makes drug-resistant tumor cells respond again to chemotherapy. The new substance blocks…
Read More
New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients
New guidelines from the American Society of Hematology “strongly recommend” using no thromboprophylaxis over using parenteral thromboprophylaxis in ambulatory patients receiving cancer chemotherapy who have low venous thromboembolism (VTE) risk, and using no thromboprophylaxis over oral thromboprophylaxis with vitamin K…
Read More
Researchers Approach Publishers About Errors in 31 Papers
Retraction Watch readers may recall the name Jennifer Byrne, whose work as a scientific sleuth we first wrote about four years ago, and have followed ever since. In a new paper in Scientometrics , Byrne, of New South Wales Health Pathology and the University of…
Read More